Bio-Thera expands partnership for biosimilar

Bio-Thera Solutions is broadening its collaboration with Intas Pharmaceuticals for the commercialization of BAT2506, a proposed biosimilar referencing Simponi®. This expansion deepens the existing partnership, granting Intas exclusive commercialization rights in specified territories. The agreement focuses on bringing this important therapeutic option to more patients, leveraging both companies' expertise in biopharmaceutical development and market access. This strategic move highlights Bio-Thera's commitment to advancing its pipeline and maximizing the global reach of its innovative treatments. The collaboration aims to enhance patient access to affordable biologic medicines.